Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, multidisciplinary study, Phase II-III clinical trial.The study is opened to the incorporation of other centers that would increase the power of the obtained results . Our hypothesis considers that using Hyperthermic Intra-abdominal Chemotherapy,HIPEC, with gemcitabine after cytoreductive surgery ,will decrease tumor progression of pancreatic cancer by reducing the neoplastic volume and subpopulation of pancreatic cancer stem cells, improving the survival of patients with pancreatic cancer, and decreasing the recurrence of the disease

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital General de Ciudad Real
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

· Resectable pancreatic adenocarcinoma

Exclusion Criteria:

• Voluntary refusal to participate in the trial

• Existence of distant disease that contraindicates the surgical treatment

• Patients with preoperative or intraoperative locoregional unresectable pancreatic cancer

• Existence of synchronous neoplastic disease

• Exclusion after perioperative anesthetic study